PodMed – Week of September 18, 2017
This week’s topics include hospital factors relative to readmission, hormone therapy, lymph node dissection in breast cancer, and the cost of bringing a new drug to market. Program notes: 0:32 Cost of R and D versus profit in new drugs 1:32 Took 7.3 years 2:35 Reaping in sales far outstrips R and D 3:32 R […]
ConclusionsThe present study demonstrates that, in plasma-derived exosomes, high baseline CDK4 mRNA levels are associated with response to palbociclib plus hormonal therapy, while the increase in TK1 and CDK9 mRNA copies/ml is associated with clinical resistance.
Waseem Abbas, Ranga Raju RaoIndian Journal of Cancer 2019 56(4):293-296Adjuvant ovarian suppression, on addition to chemotherapy, reduces the risk of breast cancer in pre-menopausal women after surgery and adjuvant hormonal therapy. Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT) showed greater benefit with exemestane in high risk females in comparison to Tamoxifen. Ovarian Function Suppression (OFS) and exemestane became the standard of care, with 30% patients experiencing grade 3 and more side effects. Much higher benefit was seen in high risk group. But there are concerns about inc...
ConclusionsBreast conservation may be considered a safe alternative in the surgical treatment of MBC. Future research should focus on better standardization of local therapy for MBC and improved reporting of outcomes.
According to a study published inAnnals of Oncology, hormone therapy worsens quality of life for women with breast cancer to a greater extent and for longer than chemotherapy.Scienmag
ConclusionIt is important to maintain a suspicion for GI tract metastasis in breast cancer patients who present with abdominal mass or GI symptoms, as this aids in prompt institution of accurate and appropriate management.
This study investigated the effects of anti-microRNA-21 (miR-21) AMO modified with CLDs on breast cancer cells without using reporter assay. The CLD-modified AMO suppressed breast cancer cell proliferation for a long duration compared to other types of AMOs. In addition, it expectedly up-regulated the miR-21-controlled expression of tumor suppressor genes. Therefore, an AMO flanked by CLDs can be a promising strategy for breast cancer treatment. PMID: 31583946 [PubMed - as supplied by publisher]
Conclusion: High p16 protein expression was associated with ER-positive, PR-negative, and HER2-negative tumors which is associated with poor prognosis. p16 protein expression may be used as a prognostic indicator to predict treatment response to hormonal therapy.
Conclusion: We need further studies on the large group of upper Egypt breast cancer patients to confirm that the level of HER-2/neu mRNA expression can be used as a marker for classified them and their response to different treatment.
Authors: Vogel L PMID: 31570552 [PubMed - in process]
You’re staring at a letter from your mammography facility. Your breast exam was normal, great. But then you see a note on the bottom: you have high breast density, which could put you at higher risk for breast cancer in the future. Now what? “The finding of dense breasts on a mammogram can be stressful and confusing for patients,” says Dr. Toni Golen, acting editor in chief of Harvard Women’s Health Watch. It’s information that may concern them, but they don’t know what to do about it. What is breast density? Breasts are composed of: lobules, which produce milk ducts, tubes that carry m...